Genelux Corporation has released a corporate presentation outlining that Olvi-Vec, its lead product candidate, is estimated to represent a billion-dollar plus annual market opportunity in the United States. Initial interim data for its trial in recurrent non-small-cell lung cancer will be available as early as mid-2024.